EVO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

EV

Mkt Cap

$493.6M

Volume

81.74K

Loading chart

EV

EVOEvotec SE American Depositary Shares

EVO

Pay with—

Available Balance0.00

EV

Mkt Cap

$504.7M

Volume

81.74K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

BIO-Europe 2026 to Convene Global Biopharma Decision-Makers in CologneBIO-Europe 2026 will host over 6,000 senior leaders from the global biopharma industry in Cologne, Germany, from November 9-11, 2026. The 32nd annual edition expands beyond partnering to become Europe's largest biopharma strategy forum, featuring seven integrated tracks covering regulatory, clinical, and manufacturing strategy, with focus on partnerships, innovation, and addressing industry challenges.GlobeNewswire Inc. · Sep 29, 2026

Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS InsiderThe global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.GlobeNewswire Inc. · Sep 7, 2026

State of the Life Sciences Industry to Be Reviewed in BCC Research's 2026 Second Quarter Outlook, Spotlighting AI-Driven Discovery, Precision Oncology, and Connected Health AdoptionBCC Research's mid-year assessment highlights AI-driven discovery, precision oncology, and connected health as major growth themes in the life sciences sector. Key opportunities include smart inhalers with AI integration, genomic profiling platforms, cardiovascular drug innovations, and in vitro toxicity testing. The sector benefits from aging populations, regulatory support for non-animal testing, and emerging market expansion, though risks include patent expirations and reimbursement variability.GlobeNewswire Inc. · Aug 25, 2026

Gilead Acquisition Spree Continues With $3 Billion Tubulis DealGilead Sciences announced a $3.15 billion acquisition of Tubulis GmbH to strengthen its oncology pipeline, adding the promising antibody-drug conjugate TUB-040 for ovarian cancer treatment. The deal includes up to $1.85 billion in contingent milestone payments. This acquisition follows Gilead's March purchase of Ouro Medicines for $1.675 billion, highlighting the company's broader pipeline expansion strategy.Benzinga · Apr 7, 2026

Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesJohnson Fistel, PLLP is investigating whether Evotec SE complied with federal securities laws following the company's announcement of its 'Horizon' restructuring initiative on March 10, 2026. The investigation focuses on potential investor losses related to Evotec's financial guidance projecting €700-780 million in revenue and €0-40 million in adjusted EBITDA for fiscal year 2026, along with €100 million in restructuring charges expected over 2026-2028.GlobeNewswire Inc. · Mar 11, 2026

Antibody Optimization Service (Affinity Maturation, Humanization, Phage Display, AI-based Computational Optimization) Market Trends Analysis and Growth Forecast Report 2025-2033The global antibody optimization service market is projected to grow from USD 1.36 billion in 2024 to USD 2.87 billion by 2033, with a CAGR of 8.81%. Growth is driven by rising prevalence of complex diseases, increased R&D investments in biologics, and advancements in computational modeling and protein engineering technologies.GlobeNewswire Inc. · Jan 21, 2026

Amgen Buys Dark Blue In $840 Million Bet On New Leukemia DrugsAmgen acquired Dark Blue Therapeutics for up to $840 million to strengthen its oncology pipeline. Dark Blue's lead candidate DBT 3757 targets acute myeloid leukemia and acute lymphoblastic leukemia. The acquisition complements Amgen's targeted protein degradation research and advances its early-stage cancer medicine strategy.Benzinga · Jan 7, 2026

MUVON Therapeutics Appoints Dr. Christine Günther as Chief Technology OfficerMUVON Therapeutics announced positive Phase 2 clinical trial results for a novel muscle precursor cell therapy treating stress urinary incontinence, demonstrating high statistical significance and an 87% responder rate. The company also appointed Dr. Christine Günther as Chief Technology Officer to advance their regenerative medicine platform.GlobeNewswire Inc. · Dec 18, 2025

Antibody Discovery Market to Reach USD 17.68 Billion by 2032, Driven by Rising Demand for Targeted Therapies and Advancements in AI Powered Antibody Engineering – SNS InsiderThe global antibody discovery market is projected to grow from USD 8.42 billion in 2024 to USD 17.68 billion by 2032, driven by increasing demand for targeted therapies and advancements in biologics for treating chronic diseases like cancer and autoimmune disorders.GlobeNewswire Inc. · Dec 7, 2025

Lead Optimization Services in Drug Discovery Market to Reach USD 10.26 Billion by 2034, Driven by Rising R&D ActivityThe global lead optimization services in drug discovery market is projected to grow from USD 4.26 billion in 2024 to USD 10.26 billion by 2034, driven by rising R&D activities, technological advancements, and increasing outsourcing trends in pharmaceutical research.GlobeNewswire Inc. · Nov 28, 2025

to start trading

EV

EVOEvotec SE American Depositary Shares

EVO

Pay with—

Available Balance0.00

Your PositionYou don't own any EVO yet.

Related Tickers

Earnings